About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings, Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(R) and its derivatives Radilex(TM) and Viprovex(R), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at http://www.immuneregen.com.
Statements about the Company's future expectations, including
statements about the potential for the Company's drug candidates, science
and technology, and all other statements in this press release other than
historical facts, are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Securities
Litigation Reform Act of 1995. The Company intends that such
forward-looking statements be subject to the safe harbors created thereby.
These future events may not occur as and when expected, if at all, and,
together with the Company's business, are subject to various risks and
uncertainties. The Company's actual results could differ materially from
|SOURCE ImmuneRegen BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved